Losartan Potassium Tablet, Film Coated
Product Images NDC 71205-675

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 71205-675). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image001 (03375ec9 0e3a 40c2 8c77 De5d9fd21876 01)

Chemical structure diagram of Losartan Potassium, the active ingredient in LOSARTAN POTASSIUM 25 mg oral film-coated tablets by Proficient Rx LP. The structure shows molecular connectivity including potassium ion (K+) and characteristic atoms such as chlorine (Cl), nitrogen (N), and carbon (C).*

FDA Label Image

Image002 (03375ec9 0e3a 40c2 8c77 De5d9fd21876 02)

A line chart comparing the percentage of patients with primary endpoint events over a study period of up to 66 months for Atenolol and Losartan potassium. The x-axis represents study months, and the y-axis shows the percentage of patients with the primary endpoint. Atenolol is shown with a dotted line, and Losartan potassium with a solid line, indicating a 13% adjusted risk reduction for Losartan potassium (p=0.021).*

FDA Label Image

Image003 (03375ec9 0e3a 40c2 8c77 De5d9fd21876 03)

A line graph comparing the percentage of patients with fatal or non-fatal stroke over study months for Atenolol (dotted line) and Losartan potassium (solid line). The x-axis represents study months from 0 to 66, and the y-axis shows the percentage of patients from 0 to 8. The graph includes an annotation noting an adjusted risk reduction of 25% with a p-value of 0.001 for Losartan potassium compared to Atenolol.*

FDA Label Image

Image004 (03375ec9 0e3a 40c2 8c77 De5d9fd21876 04)

A comparative forest plot chart showing hazard ratios (95% CI) for primary composite events and stroke (fatal/non-fatal) events between Losartan Potassium and Atenolol across different patient subgroups, including age, gender, race, ISH status, diabetes, and history of cardiovascular disease. Event rates (%) and patient numbers are listed, with the hazard ratios visually indicating favor toward either Losartan Potassium or Atenolol.*

FDA Label Image

Image005 (03375ec9 0e3a 40c2 8c77 De5d9fd21876 05)

A line graph depicting the percentage of patients with an event over a 48-month period, comparing Losartan potassium (solid line) and placebo (dotted line). The graph shows cumulative event rates increasing over time, with a reported risk reduction of 16.1% and a p-value of 0.022.*

FDA Label Image

71205-675-90 (03375ec9 0e3a 40c2 8c77 De5d9fd21876 07)

Label for Losartan Potassium 25 mg tablets, film coated, in a quantity of 90 tablets. The label shows the product contains 25 mg of Losartan Potassium USP per tablet. It is labeled by Proficient Rx LP, with NDC 71205-675-90, and manufactured by Vivimed Life Sciences Private Limited in India. The tablets are described as white, round, biconvex, debossed with 'II' on one side. Storage instructions specify 25°C (77°F).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.